Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
First Quarter Earnings Show Increased R&D Spend
Executive Summary
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.